1. United States Environmental Protection Agency (2007) Reregistration Eligibility Decision for 4-aminopyridine. Accessed on 3-21-2013 at: http://www.epa.gov/oppsrrd1/REDs/aminopyridine_red.pdf
2. Rowan MJ (1985) Central nervous system toxicity evaluation in vitro: neurophysiological approach. In: Blum K, Manzo L (eds) Neurotoxicology. Marcel Dekker, New York, pp 596–598
3. Agoston S, Van Weerden T, Westra P et al (1978) Effect of 4-aminopyridine in Eaton–Lambert syndrome. Br J Anaesth 50:383–385
4. Ball AP, Hopkinson RB, Ferrel ID et al (1979) Human botulism caused by Clostridium botulinum type E: the Birmingham outbreak. Q J Med 191:473–491
5. Lundh H, Nilsson O, Rosen I (1979) Effects of 4-aminopylidine in myasthenia gravis. J Neurol Neurosurg Psychiatry 42:171–175